1
|
Buchalet C, Loap P, Losa S, Laas E, Gaillard T, Lecuru F, Malhaire C, Huchet V, De La Rochefordiere A, Labib A, Kissel M. Long-term clinical outcomes of preoperative brachytherapy in early-stage cervical cancer. Eur J Surg Oncol 2024; 50:108342. [PMID: 38636247 DOI: 10.1016/j.ejso.2024.108342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2024] [Revised: 04/09/2024] [Accepted: 04/12/2024] [Indexed: 04/20/2024]
Abstract
OBJECTIVE The treatment of early-stage cervical cancer (CC) is primarily based on surgery. Adjuvant (chemo)radiotherapy can be necessary in presence of risk factors for relapse (tumor size, deep stromal invasion, lymphovascular space invasion (LVSI), positive margins, parametrial or lymph node involvement), increasing the risk of treatment toxicity. Preoperative brachytherapy can reduce tumor extension before surgery, potentially limiting the need for adjuvant radiotherapy. This study reports long-term clinical outcomes on efficacy and toxicity of preoperative pulse-dose-rate (PDR) brachytherapy in early-stage CC. METHODS All patients treated at Institut Curie between 2007 and 2022 for early-stage CC by preoperative brachytherapy were included. A PDR technique was used. Patients underwent hysterectomy associated with nodal staging following brachytherapy. RESULTS 73 patients were included. The median time from brachytherapy to surgery was 45 days [range: 25-78 days]. With a median follow-up of 51 months [range: 4-185], we reported 3 local (4 %), 1 locoregional (1 %) and 8 metastatic (11 %) relapses. At 10 years, OS was 84.1 % [95 % CI: 70.0-100], DFS 84.3 % [95 % CI:74.6-95.3] and LRFS 92.8 % [95 % CI:84.8-100]. Persistence of a tumor residue, observed in 32 patients (44 %), was a significant risk factor for metastatic relapse (p = 0.02) and was associated with the largest tumor size before brachytherapy (p = 0.04). Five patients (7 %) experienced grade 3 toxicity. One patient (1 %) developed grade 4 toxicity. Ten patients (14 %) received adjuvant radiotherapy, increasing the risk of lymphedema (HR 1.31, 95 % CI [1.11-1.54]; p = 0.002). CONCLUSIONS PDR preoperative brachytherapy for early-stage cervical cancer provides high long-term tumor control rates with low toxicity.
Collapse
Affiliation(s)
- C Buchalet
- Radiation Oncology Department, Institut Curie, Paris, France
| | - P Loap
- Radiation Oncology Department, Institut Curie, Paris, France
| | - S Losa
- Medical Physics Department, Institut Curie, Paris, France
| | - E Laas
- Surgical Oncology Department, Institut Curie, Paris, France
| | - T Gaillard
- Surgical Oncology Department, Institut Curie, Paris, France
| | - F Lecuru
- Surgical Oncology Department, Institut Curie, Paris, France
| | - C Malhaire
- Radiology Department, Institut Curie, Paris, France
| | - V Huchet
- Nuclear Medicine Department, Institut Curie, Paris, France
| | - A De La Rochefordiere
- Radiation Oncology Department, Centre Charlebourg-La Défense-Amethyst, La Garenne-Colombes, France
| | - A Labib
- Radiation Oncology Department, Institut Curie, Paris, France
| | - M Kissel
- Radiation Oncology Department, Institut Curie, Paris, France.
| |
Collapse
|
2
|
Oufkir N, Didelot H, Hamy A, Reyal F, Laas E. Liens entre associations de patients et industrie pharmaceutique : une analyse de la base de données publique Transparence santé. Rev Epidemiol Sante Publique 2022. [DOI: 10.1016/j.respe.2022.03.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
3
|
Hamy AS, Bonsang-Kitzis H, De Croze D, Laas E, Darrigues L, Topciu L, Menet E, Vincent-Salomon A, Lerebours F, Pierga JY, Brain E, Feron JG, Benchimol G, Lam GT, Laé M, Reyal F. Abstract P3-11-01: Interaction between molecular subtype and stromal immune infiltration dynamics in breast cancer patients treated with neoadjuvant chemotherapy. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-11-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: High levels of tumor-infiltrating lymphocytes (TILs) before neoadjuvant chemotherapy (NAC) are associated with higher pathological complete response (pCR) rates, and better survival in TNBC and HER2-positive breast cancers (BCs). We investigated the value of changes in TIL levels and final TIL levels after treatment, by evaluating lymphocyte infiltration before and after NAC in a real-life BC cohort.
Patients and methods: We assessed stromal TIL levels in 716 pre- and post-treatment matched paired specimens, according to the guidelines of the international TIL working group.
Results: Pre-NAC TIL levels were higher in tumors for which pCR was achieved than in cases of residual disease (33.9% versus 20.3%, p=0.001), in luminal tumors and TNBCs, but not in HER2-positive BCs, (pInteraction =0.001). The association between pre-NAC TIL levels and pCR was non-linear in TNBCs (p=0.005). Mean TIL levels decreased during NAC (pre-NAC TILs: 24.1% versus post-NAC TILs: 13.0%, p<0.001). This decrease was strongly associated with high pCR rates, and TIL level variation was strongly inversely correlated with pre-NAC TIL levels (r=-0.80, p<0.001). Pre-NAC TILs and disease-free survival (DFS) were associated in a non-linear manner (p<0.001). High post-NAC TIL levels were associated with aggressive tumor characteristics and with impaired DFS in HER2-positive BCs (HR=1.04, CI [1.02-1.06], p=0.001), but not in luminal tumors or TNBCs (pInteraction =0.04).
Conclusion: The associations of pre, post-NAC TIL levels with response to treatment and DFS differ between BC subtypes and may deviate from linearity. The characterization of immune subpopulations may improve our understanding of the complex interactions between pre- or post-NAC setting, BC subtype, response to treatment and prognosis.
Citation Format: Hamy A-S, Bonsang-Kitzis H, De Croze D, Laas E, Darrigues L, Topciu L, Menet E, Vincent-Salomon A, Lerebours F, Pierga J-Y, Brain E, Feron J-G, Benchimol G, Lam G-T, Laé M, Reyal F. Interaction between molecular subtype and stromal immune infiltration dynamics in breast cancer patients treated with neoadjuvant chemotherapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-11-01.
Collapse
Affiliation(s)
- A-S Hamy
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - H Bonsang-Kitzis
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - D De Croze
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - E Laas
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - L Darrigues
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - L Topciu
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - E Menet
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - A Vincent-Salomon
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - F Lerebours
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - J-Y Pierga
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - E Brain
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - J-G Feron
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - G Benchimol
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - G-T Lam
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - M Laé
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - F Reyal
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| |
Collapse
|
4
|
Hamy AS, Pierga JY, Sabaila A, Laas E, Bonsang-Kitzis H, Laurent C, Vincent-Salomon A, Cottu P, Lerebours F, Rouzier R, Lae M, Reyal F. Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer. Ann Oncol 2018; 28:2233-2240. [PMID: 28911063 DOI: 10.1093/annonc/mdx309] [Citation(s) in RCA: 66] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Background The role of tumor-infiltrating lymphocytes (TILs) in breast cancer has been extensively studied over the last decade. High TILs levels have been associated with pathological response rate in the neoadjuvant setting and with better outcomes in the adjuvant setting. However, little attention has been paid to changes in TILs and residual TIL levels after neoadjuvant chemotherapy (NAC). We investigated TIL levels before, after chemotherapy, and their dynamics during treatment; and we assessed the correlation of these levels with response to NAC and prognosis. Materials and methods We identified 175 patients with primary HER2-positive breast cancers receiving NAC+/- trastuzumab between 2002 and 2011. Microbiopsy specimens and paired surgical samples were evaluated for stromal lymphocyte infiltration. Univariate and multivariate analyses were carried out to assess the association of clinical and pathological factors with pathological complete response (pCR) and disease-free survival. Results Baseline TIL levels were not significantly associated with pCR. TIL levels decreased during treatment in 78% of the patients. The magnitude of the decrease was strongly associated with pCR. After chemotherapy, TIL levels were high in tumors displaying aggressive patterns (high residual cancer burden score, mitotic index >22, tumor cellularity >5%). In the population with residual disease, TIL levels >25% at the end of NAC were significantly associated with an adverse outcome (TILs >25%, HR = 7.98, P = 0.009) after multivariate analyses including BMI, post-NAC mitotic index and tumor grade. Conclusion A decrease in TIL levels during chemotherapy was positively associated with response to treatment. In tumor failing to achieve pCR, post-NAC lymphocytic infiltration was associated with higher residual tumor burden and adverse clinical outcome. Further studies are required to characterize immune infiltration in residual disease to identify candidates who could benefit from second-line therapy trials including immune checkpoint inhibitors.
Collapse
Affiliation(s)
- A-S Hamy
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, PSL Research University, Institut Curie, Paris.,INSERM, U932 Immunity and Cancer, Paris
| | - J-Y Pierga
- Department of Medical Oncology, Institut Curie, Paris.,Faculty of Medicine, Paris Descartes University, Paris
| | - A Sabaila
- Departments of Surgery, Institut Curie, Paris
| | - E Laas
- Departments of Surgery, Institut Curie, Paris
| | - H Bonsang-Kitzis
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, PSL Research University, Institut Curie, Paris.,INSERM, U932 Immunity and Cancer, Paris.,Departments of Surgery, Institut Curie, Paris
| | - C Laurent
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, PSL Research University, Institut Curie, Paris.,INSERM, U932 Immunity and Cancer, Paris
| | | | - P Cottu
- Department of Medical Oncology, Institut Curie, Paris
| | - F Lerebours
- Department of Medical Oncology, Institut Curie, Paris
| | - R Rouzier
- Departments of Surgery, Institut Curie, Paris.,Equipe d'Accueil 7285, Risk and Safety in Clinical Medicine for Women and Perinatal Health, University Versailles-Saint-Quentin, 2 av de la source de la Biévre, 78180 Montigny-le-Bretonneux, France
| | - M Lae
- Department of Pathology, Institut Curie, Paris, France
| | - F Reyal
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, PSL Research University, Institut Curie, Paris.,INSERM, U932 Immunity and Cancer, Paris.,Departments of Surgery, Institut Curie, Paris
| |
Collapse
|
5
|
Hamy AS, Val de Lièvre C, Laas E, Darrigues L, Priour M, Guerin J, Balezeau T, Livartowski A, Pierga JY, Escalup L, Asselain B, Rouzier R, Lae M, Decroze D, Pinheiro A, Laurent C, Reyal F. Abstract P3-06-11: Withdrawn. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-06-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- A-S Hamy
- Institut Curie, Paris, France; U932, Immunity and Cancer, INSERM, Institut Curie, Paris, France; Institut Curie, Paris, France
| | - C Val de Lièvre
- Institut Curie, Paris, France; U932, Immunity and Cancer, INSERM, Institut Curie, Paris, France; Institut Curie, Paris, France
| | - E Laas
- Institut Curie, Paris, France; U932, Immunity and Cancer, INSERM, Institut Curie, Paris, France; Institut Curie, Paris, France
| | - L Darrigues
- Institut Curie, Paris, France; U932, Immunity and Cancer, INSERM, Institut Curie, Paris, France; Institut Curie, Paris, France
| | - M Priour
- Institut Curie, Paris, France; U932, Immunity and Cancer, INSERM, Institut Curie, Paris, France; Institut Curie, Paris, France
| | - J Guerin
- Institut Curie, Paris, France; U932, Immunity and Cancer, INSERM, Institut Curie, Paris, France; Institut Curie, Paris, France
| | - T Balezeau
- Institut Curie, Paris, France; U932, Immunity and Cancer, INSERM, Institut Curie, Paris, France; Institut Curie, Paris, France
| | - A Livartowski
- Institut Curie, Paris, France; U932, Immunity and Cancer, INSERM, Institut Curie, Paris, France; Institut Curie, Paris, France
| | - J-Y Pierga
- Institut Curie, Paris, France; U932, Immunity and Cancer, INSERM, Institut Curie, Paris, France; Institut Curie, Paris, France
| | - L Escalup
- Institut Curie, Paris, France; U932, Immunity and Cancer, INSERM, Institut Curie, Paris, France; Institut Curie, Paris, France
| | - B Asselain
- Institut Curie, Paris, France; U932, Immunity and Cancer, INSERM, Institut Curie, Paris, France; Institut Curie, Paris, France
| | - R Rouzier
- Institut Curie, Paris, France; U932, Immunity and Cancer, INSERM, Institut Curie, Paris, France; Institut Curie, Paris, France
| | - M Lae
- Institut Curie, Paris, France; U932, Immunity and Cancer, INSERM, Institut Curie, Paris, France; Institut Curie, Paris, France
| | - D Decroze
- Institut Curie, Paris, France; U932, Immunity and Cancer, INSERM, Institut Curie, Paris, France; Institut Curie, Paris, France
| | - A Pinheiro
- Institut Curie, Paris, France; U932, Immunity and Cancer, INSERM, Institut Curie, Paris, France; Institut Curie, Paris, France
| | - C Laurent
- Institut Curie, Paris, France; U932, Immunity and Cancer, INSERM, Institut Curie, Paris, France; Institut Curie, Paris, France
| | - F Reyal
- Institut Curie, Paris, France; U932, Immunity and Cancer, INSERM, Institut Curie, Paris, France; Institut Curie, Paris, France
| |
Collapse
|
6
|
Hamy-Petit AS, Lam GT, Laas E, Darrigues L, Balezeau T, Guerin J, Livartowski A, Sadacca B, Pierga JY, Vincent-Salomon A, Bidard FC, Lerebours F, Brain E, Becette V, Rouzier R, Lae M, Reyal F. Abstract P2-03-04: Lymphovascular invasion in breast carcinoma following neodjuvant chemotherapy is a strong prognosis factor. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-03-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose : Lymphovascular invasion (LVI) is a poor prognosis factor in breast cancer (BC), but data on its value in the neoadjuvant setting is scarce. This study evaluates the relationships between post-NAC LVI and prognosis in BC.
Methods: We identified 1197 patients with primary BC receiving NAC +/- trastuzumab between 2002 and 2011. Information on LVI in post-NAC surgical specimen was retrieved from review of medical charts. Univariate and multivariate analyses were performed to assess the association of clinical, pathological factors with disease free survival (DFS) and overall survival (OS) was assessed using a cox proportional hazard model.
Results: On 1197 tumors, 528 were luminal (44.1%), 375 were triple negative breast cancer (TNBC) (31.3%) and 294 were HER2-positive (24.6%). On post-NAC surgical specimens, LVI was present in 302 (25.2%), absent in 531 (44.4%), and was not mentionned in 364 cases (30.4%). The presence of post-NAC LVI was associated with an impaired DFS (HR=2.17, 95 CI [1.65 - 2.86], p<0.001) and the magnitude of this impact varied by BC subtype (p-value for interaction=0.02), (luminal BC: HR=1.75, p=0.006; TNBC : HR=2.77, p<0.001 ; HER2-positive BC : HR=5.12, p<0.001).
Table 1 Univariate analysis and multivariate analysis on DFS (whole population) Univariate Multivariate VariableClassHRClpHRCIpAge< 451 0.35 45-550.82[0.62 - 1.08] >550.87[0.64 - 1.19] Menopausal statuspremenopausal1.04[0.81 - 1.34]0.75 postmenopausal1 BMI class19-251 < 191.24[0.75 - 2.05]0.41 > 251.36[1.06 - 1.75]0.01 Tumor sizeT1-T21 T31.77[1.38 - 2.27]<0.011.77[ 1.32 - 2.38 ]<0.001Clinical nodal statusN01 N1-N2-N31.35[1.05 - 1.72]0.021.43[ 1.07 - 1.91 ]0.016HistologyDuctal1 Other1.24[0.87 - 1.78]0.24 GradeGrade I-II1 III1.24[0.87 - 1.78]0.07 Ki 67<201 >201.54[1.06 - 2.22]0.02 Mitotic index≤221 >221.18[0.9 - 1.53]0.23 DCIS componentno1 yes1.33[0.88 - 2.01]0.18 Pre-NAC LVIno1 yes1.35[0.88 - 2.01]0.09 ER statusnegative1 positive0.72[0.56 - 0.91]<0.01 PR statusnegative1 positive0.66[0.51 - 0.85]<0.01 HER2 statusnegative1 positive0.84[0.62 - 1.14]0.26 BC subtypeluminal1 TNBC1.53[1.17 - 2]<0.012.67[ 1.93 - 3.69 ]<0.001 HER20.99[0.72 - 1.38]0.971.25[ 0.82 - 1.88 ]0.299Post NAC parametersPost-NAC LVI (breast)no1 yes2.17[1.65 - 2.86]<0.012.3[ 1.72 - 3.08 ]<0.001pCRNo pCR1 pCR0,4[0.27 - 0.59]<0.01 Pathological nodal involvement0 1-31.48[1.11 - 1.97]<0.01 ≥4 N+3.13[2.34 - 4.19]<0.01 RCB class01 10.97[0.36 - 2.64]0.96 22.88[1.69 - 4.89]<0.01 35.21[3.01 - 9.02]<0.01 ER: oestrogene receptor PR: progesteron receptor RCB: residual cancer burden
Post-NAC LVI was an independent predictor of poor DFS, that overwhelmed the prognostic impact of pathological complete response in all 3 BC subtypes. Post-NAC LVI was also an independent predictor of poor OS in the whole cohort and in all BC subtypes.
Table 1 resumes univariate and multivariate analysis on DFS in whole population.
Conclusion: Post-NAC LVI is a strong independent prognostic factor associated with poor DFS and OS, that (i) should be systematically mentioned in pathological reports following NAC and (ii) could be used to select high risk patients candidates to second line trials in the post-neoadjuvant window.
Citation Format: Hamy-Petit A-S, Lam G-T, Laas E, Darrigues L, Balezeau T, Guerin J, Livartowski A, Sadacca B, Pierga J-Y, Vincent-Salomon A, Bidard F-C, Lerebours F, Brain E, Becette V, Rouzier R, Lae M, Reyal F. Lymphovascular invasion in breast carcinoma following neodjuvant chemotherapy is a strong prognosis factor [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-03-04.
Collapse
Affiliation(s)
- A-S Hamy-Petit
- Institut Curie, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - G-T Lam
- Institut Curie, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - E Laas
- Institut Curie, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - L Darrigues
- Institut Curie, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - T Balezeau
- Institut Curie, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - J Guerin
- Institut Curie, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - A Livartowski
- Institut Curie, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - B Sadacca
- Institut Curie, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - J-Y Pierga
- Institut Curie, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - A Vincent-Salomon
- Institut Curie, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - F-C Bidard
- Institut Curie, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - F Lerebours
- Institut Curie, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - E Brain
- Institut Curie, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - V Becette
- Institut Curie, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - R Rouzier
- Institut Curie, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - M Lae
- Institut Curie, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - F Reyal
- Institut Curie, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| |
Collapse
|
7
|
Pirot F, Laas E, Girard G. [Can salpingectomy be proposed first line in case of ectopic pregnancy?]. ACTA ACUST UNITED AC 2016; 44:526-7. [PMID: 27568412 DOI: 10.1016/j.gyobfe.2016.07.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2016] [Accepted: 07/13/2016] [Indexed: 11/30/2022]
Affiliation(s)
- F Pirot
- Service de gynécologie-obstétrique, hôpital Armand-Trousseau, AP-HP, 26, avenue du Docteur-Arnold-Netter, 75012 Paris, France.
| | - E Laas
- Service de gynécologie-obstétrique, hôpital Armand-Trousseau, AP-HP, 26, avenue du Docteur-Arnold-Netter, 75012 Paris, France
| | - G Girard
- Service de gynécologie-obstétrique, hôpital Armand-Trousseau, AP-HP, 26, avenue du Docteur-Arnold-Netter, 75012 Paris, France
| |
Collapse
|
8
|
Lorain P, Laas E, Girard G. [Premature rupture of membranes between 34 et 36+6weeks: How to manage?]. Gynecol Obstet Fertil 2016; 44:248-249. [PMID: 27053040 DOI: 10.1016/j.gyobfe.2016.03.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/09/2016] [Accepted: 02/11/2016] [Indexed: 06/05/2023]
Affiliation(s)
- P Lorain
- Service de gynécologie obstétrique, hôpital Armand-Trousseau, 26, avenue du Dr-Arnold-Netter, 75012 Paris, France
| | - E Laas
- Service de gynécologie obstétrique, hôpital Armand-Trousseau, 26, avenue du Dr-Arnold-Netter, 75012 Paris, France
| | - G Girard
- Service de gynécologie obstétrique, hôpital Armand-Trousseau, 26, avenue du Dr-Arnold-Netter, 75012 Paris, France.
| |
Collapse
|
9
|
Laas E, Touboul C, Kerdraon O, Catteau-Jonard S. Mastites inflammatoires et infectieuses du sein en dehors de la grossesse et de la période d’allaitement : recommandations. ACTA ACUST UNITED AC 2015; 44:996-1016. [DOI: 10.1016/j.jgyn.2015.09.055] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2015] [Revised: 09/25/2015] [Accepted: 09/25/2015] [Indexed: 10/22/2022]
|
10
|
Lavoué V, Fritel X, Antoine M, Beltjens F, Bendifallah S, Boisserie-Lacroix M, Boulanger L, Canlorbe G, Catteau-Jonard S, Chabbert-Buffet N, Chamming's F, Chéreau E, Chopier J, Coutant C, Demetz J, Guilhen N, Fauvet R, Kerdraon O, Laas E, Legendre G, Mathelin C, Nadeau C, Thomassin Naggara I, Ngô C, Ouldamer L, Rafii A, Roedlich MN, Seror J, Séror JY, Touboul C, Uzan C, Daraï E. Tumeurs bénignes du sein : recommandations pour la pratique clinique du Collège national des gynécologues et obstétriciens français (CNGOF) – Texte court. ACTA ACUST UNITED AC 2015; 44:1049-64. [DOI: 10.1016/j.jgyn.2015.09.033] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2015] [Accepted: 09/18/2015] [Indexed: 11/29/2022]
|
11
|
Lavoué V, Fritel X, Chopier J, Roedlich MN, Chamming's F, Mathelin C, Bendifallah S, Boisserie-Lacroix M, Canlorbe G, Chabbert-Buffet N, Coutant C, Guilhen N, Fauvet R, Laas E, Legendre G, Thomassin Naggara I, Ngô C, Ouldamer L, Seror J, Touboul C, Daraï E. [Clinical practice guidelines: Benign breast tumor--Aims, methods and organization]. J Gynecol Obstet Hum Reprod 2015; 44:898-903. [PMID: 26527015 DOI: 10.1016/j.jgyn.2015.09.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2015] [Accepted: 09/18/2015] [Indexed: 06/05/2023]
Abstract
Conversely to breast cancer, few data and guidelines are available to explore and manage benign breast disorders. Therefore, the Collège national des gynécologues et obstétriciens français (CNGOF - French College of Gynaecologists and Obstetricians) decided to establish clinical practice guidelines for benign breast tumour (BBT). CNGOF appointed a committee with responsibility for selecting experts, compiling questions and summarizing the recommendations. The summary of valid scientific data for each question analyzed by the experts included a level of evidence, based on the quality of the data available and defined accordingly rating scheme developed by the Haute Autorité de santé (French National Authority for Health).
Collapse
Affiliation(s)
- V Lavoué
- Service de gynécologie, CHU de Rennes, ER440, Oncogenesis, Stress and Signaling, labelisé Inserm, CRLCC Eugène-Marquis, université de Rennes 1, 35000 Rennes, France; Collège national des gynécologues et obstétriciens français, 91, boulevard Sébastopol, 75002 Paris, France.
| | - X Fritel
- Université de Poitiers, CIC 1402, CHU de Poitiers, 86021 Poitiers, France; CESP Inserm U1018, 94270 Le Kremlin-Bicêtre, France
| | - J Chopier
- Service de radiologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - M-N Roedlich
- Service de radiologie, hôpital Hautepierre, 1, avenue Molière, 67100 Strasbourg, France
| | - F Chamming's
- Service de radiologie, hôpital européen Georges-Pompidou, AP-HP, 15, rue Leblanc, 75015 Paris, France
| | - C Mathelin
- Unité de sénologie, hôpital de Hautepierre, CHRU de Strasbourg, avenue Molière, 67200 Strasbourg, France
| | - S Bendifallah
- Inserm UMRS707, service de gynécologie-obstétrique et médecine de la reproduction, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - M Boisserie-Lacroix
- Service de radiologie, centre régional de lutte contre le cancer Bergognié, 33000 Bordeaux, France
| | - G Canlorbe
- Service de gynécologie-obstétrique et médecine de la reproduction, hôpital Tenon, AP-HP, Inserm UMRS938, 4, rue de la Chine, 75020 Paris, France
| | - N Chabbert-Buffet
- Service de gynécologie-obstétrique et médecine de la reproduction, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - C Coutant
- Service de chirurgie, centre régional de lutte contre le cancer Georges-François-Leclerc, 21000 Dijon, France
| | - N Guilhen
- Service de gynécologie-obstétrique, CHU de Poitiers, 2, rue de la Milétrie, BP 577, 86021 Poitiers cedex, France
| | - R Fauvet
- Service de gynécologie-obstétrique, CHU de Caen, université de Basse-Normandie, Inserm U1199, BIOTICLA, avenue de la Côte-de-Nacre, 14033 Caen cedex 09, France
| | - E Laas
- Service de gynécologie-obstétrique et médecine de la reproduction, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - G Legendre
- Service de gynécologie-obstétrique, CHU d'Angers, CESP Inserm U1018, 49100 Angers, France
| | - I Thomassin Naggara
- Service de radiologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - C Ngô
- Service de chirurgie cancérologique, gynécologique et du sein, hôpital européen Georges-Pompidou, AP-HP, université Paris Descartes, 15, rue Leblanc, 75015 Paris, France
| | - L Ouldamer
- Unité Inserm 1069, département de gynécologie, hôpital Bretonneau, centre hospitalier régional universitaire de Tours, faculté de médecine François-Rabelais, 2, boulevard Tonnellé, 37044 Tours, France
| | - J Seror
- Cabinet médical, 146, avenue Ledru-Rollin, 75011 Paris, France; Service d'échographie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - C Touboul
- Service de gynécologie-obstétrique, CHI, 40, avenue de Verdun, 94000 Créteil, France
| | - E Daraï
- Service de gynécologie-obstétrique et médecine de la reproduction, hôpital Tenon, AP-HP, Inserm UMRS938, 4, rue de la Chine, 75020 Paris, France
| |
Collapse
|
12
|
Touboul C, Laas E, Rafii A. [Exploration of breast inflammation excluding pregnancy and breastfeeding: Guidelines]. ACTA ACUST UNITED AC 2015; 44:913-20. [PMID: 26527011 DOI: 10.1016/j.jgyn.2015.09.041] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2015] [Accepted: 09/18/2015] [Indexed: 01/04/2023]
Abstract
Breast inflammation, excluding breast-feeding and pregnancy, is a rare breast pathology. We conducted a PubMed database search of all studies focusing on mastitis or breast inflammation exploration. While the most frequent aetiologies are infectious and inflammatory, inflammatory breast cancer can be diagnosed (LE2). Aetiologic diagnostic is difficult due to the absence of any clinical and imaging specific signs (LE3). The presence of mass, suspect lymph nodes or skin thickening in a woman older than 40 years old should orient toward inflammatory breast cancer (LE3). A suspect lesion must lead to perform a biopsy under sonography (grade A). In the absence of evidence for a malignant pathology after initial evaluation, we recommend starting an antibiotic treatment (grade C) with a clinical follow-up at the end of the treatment (grade B). If the symptoms persist, we recommend a new imaging (± MRI) (grade C) and a biopsy (grade C). Benign inflammatory pathologies may require a biopsy to exclude an inflammatory breast cancer and precise the diagnosis. Their specific management and treatment are presented in detail in the following chapters and may involve steroids.
Collapse
Affiliation(s)
- C Touboul
- Service de gynécologie-obstétrique et médecine de la reproduction, centre hospitalier intercommunal de Créteil, faculté de médecine de Créteil UPEC - Paris XII, 40, avenue de Verdun, 94000 Créteil, France; UMR Inserm U965, angiogenèse et recherche translationnelle, 75010 Paris, France.
| | - E Laas
- Service de gynécologie-obstétrique et médecine de la reproduction, hôpital Tenon, 4, rue de la Chine, 75020 Paris, France
| | - A Rafii
- Stem Cell and Microenvironment Laboratory, Weill Cornell Medical College in Qatar (WCMC-Q), Education City, Qatar Foundation, Doha, Qatar
| |
Collapse
|
13
|
Rossi L, Laas E, Mallon P, Vincent-Salomon A, Guinebretiere JM, Lerebours F, Rouzier R, Pierga JY, Reyal F. Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma. Br J Cancer 2015; 113:996-1002. [PMID: 26379080 PMCID: PMC4651130 DOI: 10.1038/bjc.2015.239] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Revised: 06/12/2015] [Accepted: 06/04/2015] [Indexed: 12/18/2022] Open
Abstract
Background: Inconsistencies between mitotic index (MI) and Ki67 measures have been identified in many breast tumour samples. The aim of this study was to describe the prognosis of hormone receptor-positive (HR+) HER2− tumours having discrepant MI and Ki67. Methods: We included a cohort of breast cancer patients initially treated by surgery between 2001 and 2005 in the Institut Curie. Breast cancer-specific survival (BCSS) and disease-free survival (DFS) were analysed according to three proliferation groups: high MI/high Ki67 (MI=3, Ki67>20%), low MI/low Ki67 (MI<3, Ki67⩽20%) and discrepant (high MI/low Ki67 or low MI/high Ki67). Results: Among the 1430 patients, 19.6% had discrepant Ki67 and MI, 11.6% had high markers and 68.8% had low markers. The 5-year BCSS was 95.8%, 95% CI (0.93–0.98) in the discrepant group, 99.3%, 95% CI (0.993–0.999) in the low-proliferation group and 91.8%, 95% CI (0.88–0.96) in the high-proliferation group. In multivariate analysis, the survival of the discrepant group was lower than that of the low-proliferation group: BCSS hazard ratio (HR)=3.01 (1.32–6.84; P=0.008) and DFS HR=2.07, 95% CI (1.31–3.26; P=0.002). Among grade 2 tumours in multivariate analysis, DFS of the discrepant group was lower than that of the low MI/low Ki67 group: HR=1.98, 95% CI (1.14–3.46), P=0.02. Regarding BCSS, the obtained results were similar. Conclusion: The prognosis of patients with discrepant MI and Ki67 appears intermediate between that of low MI/low Ki67 and high MI/high Ki67 groups. These markers should be jointly analysed to clarify prognosis.
Collapse
Affiliation(s)
- L Rossi
- Département de chirurgie, Institut Curie, 75005 Paris, France
| | - E Laas
- Service de Gynécologie-Obstétrique, Hôpital Tenon, 75020 Paris, France
| | - P Mallon
- Craigavon Area Hospital Breast Unit BT63 5QQ, Portadown, Northern Ireland
| | - A Vincent-Salomon
- Département de biologie des tumeurs, Institut Curie, 75005 Paris, France
| | - J-M Guinebretiere
- Département de biologie des tumeurs, Institut Curie, 75005 Paris, France
| | - F Lerebours
- Département d'oncologie médicale, Institut Curie, 75005 Paris, France
| | - R Rouzier
- Département de chirurgie, Institut Curie, 75005 Paris, France.,Equipe d'Accueil 7285, 'Risk and Safety in Clinical Medicine for women and Perinatal Health', University Versailles-Saint-Quentin, 78180 Montigny-le-Bretonneux, France
| | - J-Y Pierga
- Département d'oncologie médicale, Institut Curie, 75005 Paris, France
| | - F Reyal
- Département de chirurgie, Institut Curie, 75005 Paris, France.,Département de recherche translationnelle, Equipe résidu tumoral et réponse au traitement, Institut Curie, 75005 Paris, France.,INSERM U932 Immunity and Cancer, Institut Curie, 75005 Paris, France
| |
Collapse
|
14
|
Cohen J, Thomin A, Mathieu D'Argent E, Laas E, Canlorbe G, Zilberman S, Belghiti J, Thomassin-Naggara I, Bazot M, Ballester M, Daraï E. Fertility before and after surgery for deep infiltrating endometriosis with and without bowel involvement: a literature review. Minerva Ginecol 2014; 66:575-587. [PMID: 25373015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
AIM Endometriosis affects from 10% to 15% of women of childbearing age and 20% of these women have deep infiltrating endometriosis (DIE). The goal of this review was to assess the impact of various locations of DIE on spontaneous fertility and the benefit of surgery and Medically Assisted Reproduction (MAR) (in vitro fertilization and intrauterine insemination) on fertility outcomes. METHODS MEDLINE search for articles on fertility in women with DIE published between 1990 and April 2013 using the following terms: "deep infiltrative endometriosis", "colorectal", "bowel", "rectovaginal", "uterosacral", "vaginal", "bladder" and "fertility" or "infertility". Twenty-nine articles reporting fertility outcomes in 2730 women with DIE were analysed. RESULTS Among the women with DIE and no bowel involvement (N.=1295), no preoperative data on spontaneous pregnancy rate (PR) were available. The postoperative spontaneous PR rate in these women was 50.5% (95% Confidence Interval [CI] =46.8-54.1) and overall PR (spontaneous pregnancies and after MAR) was 68.3% (95% CI=64.9-71.7). No evaluation of fertility outcome according to locations of DIE was feasible. For women with DIE with bowel involvement without surgical management (N.=115), PR after MAR was 29%; 95% CI=20.7-37.4). For those with bowel involvement who were surgically managed (N.=1320), postoperative spontaneous PR was 28.6% (95% CI=25-32.3) and overall postoperative PR was 46.9% (95% CI=42.9-50.9). CONCLUSION For women with DIE without bowel involvement, surgery alone offers a high spontaneous PR. For those with bowel involvement, the low spontaneous and relatively high overall PR suggests the potential benefit of combining surgery and MAR.
Collapse
Affiliation(s)
- J Cohen
- Department of Gynecology and Obstetrics Hôpital Tenon, Assistance Publique des Hôpitaux de Paris Université Pierre et Marie Curie Paris 6 GRC 6-UPMC Centre Expert en Endométriose (C3E), Paris, France -
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Debras E, Revaux A, Bricou A, Laas E, Tigaizin A, Benbara A, Carbillon L. [Obstetric and neonatal outcomes of adolescent pregnancies: a cohort study in a hospital in Seine-Saint-Denis France]. ACTA ACUST UNITED AC 2014; 42:579-84. [PMID: 24996878 DOI: 10.1016/j.gyobfe.2014.04.012] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2013] [Accepted: 04/03/2014] [Indexed: 11/18/2022]
Abstract
OBJECTIVES The aim of this study was to describe the characteristics, monitoring, obstetrical complications, childbirth and neonatal outcomes of pregnancies among minors in a cohort of adolescents from Seine-Saint-Denis (France). PATIENTS AND METHODS This is a retrospective, cohort, comparative study, conducted from January 1, 1996 to July 31, 2011, made from the database of Jean-Verdier hospital in Seine-Saint-Denis. Three groups were established: patients aged less than 16 years old, patients aged over 16 years old and under 18 years old compared to a group consisting of older primiparas from 18 to 25 years old. The criteria considered were the characteristics of pregnancy, terms of delivery, neonatal outcome and conduct of post-partum. RESULTS Minor patients were statistically more likely to be single, student, smoking and anemia compared to young adults. The obstetrical care was lower for minor compared to the control group with a number of consultations and ultrasounds lower (P < 0.001). Obstetrical complications were similar in the three groups outside of preterm labor. Adolescentes under 16 years old had a higher preterm delivery risk in multivariate analysis (RR = 0.33 CI 95% [0.12; 0.90] P = 0.03). Adolescents had fewer cesarean and instrumental deliveries (P < 0.05). DISCUSSION AND CONCLUSION Teenage pregnancy remains an important managing issue for maternities, particularly from a social standpoint. On the medical side, one preterm delivery appears to be more common among these adolescents.
Collapse
Affiliation(s)
- E Debras
- Service de gynécologie obstétrique, université Paris 13, hôpital Jean-Verdier, Assistance Publique-Hôpitaux de Paris, avenue du 14-juillet, 93140 Bondy, France
| | - A Revaux
- Service de gynécologie obstétrique, université Paris 13, hôpital Jean-Verdier, Assistance Publique-Hôpitaux de Paris, avenue du 14-juillet, 93140 Bondy, France.
| | - A Bricou
- Service de gynécologie obstétrique, université Paris 13, hôpital Jean-Verdier, Assistance Publique-Hôpitaux de Paris, avenue du 14-juillet, 93140 Bondy, France
| | - E Laas
- Service de gynécologie obstétrique, université Paris 6, hôpital Tenon, Assistance Publique-Hôpitaux de Paris, 4, rue de la Chine, 75020 Paris, France
| | - A Tigaizin
- Service de gynécologie obstétrique, université Paris 13, hôpital Jean-Verdier, Assistance Publique-Hôpitaux de Paris, avenue du 14-juillet, 93140 Bondy, France
| | - A Benbara
- Service de gynécologie obstétrique, université Paris 13, hôpital Jean-Verdier, Assistance Publique-Hôpitaux de Paris, avenue du 14-juillet, 93140 Bondy, France
| | - L Carbillon
- Service de gynécologie obstétrique, université Paris 13, hôpital Jean-Verdier, Assistance Publique-Hôpitaux de Paris, avenue du 14-juillet, 93140 Bondy, France
| |
Collapse
|
16
|
Laas E, Deis S, Haddad B, Kayem G. Comparaison de la fréquence des complications maternelles de la nifédipine et de la nicardipine en cas de menace d’accouchement prématuré à membranes intactes : étude historique portant sur deux périodes consécutives. ACTA ACUST UNITED AC 2012; 41:631-7. [DOI: 10.1016/j.jgyn.2012.04.020] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2011] [Revised: 04/18/2012] [Accepted: 04/20/2012] [Indexed: 11/25/2022]
|
17
|
Rouzier R, Chereau E, Laas E, Genin A, Bendifallah S, Gligorov J. 49P Cost-Effectiveness Evaluation of The 21-Gene Breast Cancer Test in France. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(19)65711-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
18
|
Laas E. Cardiopathies congénitales et prématurité : une étude en population. Rev Epidemiol Sante Publique 2012. [DOI: 10.1016/j.respe.2011.12.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
19
|
Chereau E, Vataire AL, Laas E, Genin AS, Aballéa S, Rouzier R. P1-10-06: Economic Analysis of Chemotherapy Costs for Adjuvant Therapy in Breast Cancer in France. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p1-10-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Total costs of adjuvant chemotherapy can be estimated using different perspectives. To date, only few studies are available in France and only few of these studies have incorporated all the relevant cost items. Indeed the total cost of adjuvant chemotherapy for breast cancer should include not only the drug costs and their administration but also supportive care, transportation and part of the work absenteeism, because all these costs are borne by the French social security. The study objective was to estimate the total costs of adjuvant chemotherapy in France using two different perspectives: the French social security and society.
Methods: We conducted a retrospective study to calculate the total cost of first line adjuvant chemotherapy for breast cancer in France. We developed an electronic CRF to collect clinical data, chemotherapy drug details, side effects and personal data such as the type of transportation from home to hospital for chemotherapy treatments and duration of work absenteeism. We added the cost of medical consultations, radiology and biology. We also calculated the exact cost of paramedical time and material. All data were collected after patient's acceptance from clinical records and by phone. Medical resource data were collected from patients’ files for which data were recorded in February 2010 in Tenon hospital (Paris). Unit costs were collected from the French medical insurance database, and other public sources such as national statistics and the technical agency for hospitalization information.
Results: We collected data from 30 patients who had adjuvant chemotherapy for breast cancer. Median age was 57.7 years and 37.9% of patients had a regular work. Using the social security perspective, the mean cost (+/− SD) for pre chemotherapy exams and management (biology, oncologist consultation, implantable port system) was €320 +/−€32. For each chemotherapy cycle, the costs of chemotherapy drugs, preventive medications and chemotherapy administration were €1267 +/− €1424. The cost of chemotherapy adverse events was €405 +/− €829 and €39 +/− €28 for usual monitoring of chemotherapy (biology tests and medical consultations). Transportation costs were estimated at €11 +/− €12 and sick leave payments at €445 +/− €521. The mean total cost per cycle was €1806 +/− €1226 per chemotherapy cycle and €12724 +/− €8426 for the whole adjuvant chemotherapy regimen. Using a broader societal perspective, the total cost of chemotherapy was €14668 +/− €9707 per patient, as it included the full cost of lost productivity due to work absenteeism.
Conclusion: We reported the first cost analysis of adjuvant chemotherapy for breast cancer in France using two different perspectives (the French social security and the society). Using the social security perspective, chemotherapy drugs and their administration accounted for 70% of the total cost of chemotherapy against 60% when using the societal perspective.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-10-06.
Collapse
Affiliation(s)
- E Chereau
- 1Tenon — APHP, Paris, France; Creativ-Ceutical, Paris, France
| | - A-L Vataire
- 1Tenon — APHP, Paris, France; Creativ-Ceutical, Paris, France
| | - E Laas
- 1Tenon — APHP, Paris, France; Creativ-Ceutical, Paris, France
| | - A-S Genin
- 1Tenon — APHP, Paris, France; Creativ-Ceutical, Paris, France
| | - S Aballéa
- 1Tenon — APHP, Paris, France; Creativ-Ceutical, Paris, France
| | - R Rouzier
- 1Tenon — APHP, Paris, France; Creativ-Ceutical, Paris, France
| |
Collapse
|
20
|
Bücker J, Laas E. Das Schleimhautrelief des Bulbus duodeni und seine Abänderungen bei Entzündungen und Lymphfollikelhyperplasien. ROFO-FORTSCHR RONTG 2009. [DOI: 10.1055/s-0029-1227110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
21
|
Laas E. [Further results of fluorescent macroscopy]. Zentralbl Allg Pathol 1965; 107:129-30. [PMID: 5215735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|